Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.62 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.62 |
| ▸ | TFEB | P19484 | 1/20 | 0.58 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095406 | 1.00 | NFE2L2 (0.62) | NFE2L2TRPA1TFEBCYP1A1CYP1A2 | |
| SCHEMBL1603719 | 0.86 | NFE2L2 (0.79) | NFE2L2TRPA1TFEBCYP1A1CYP1A2 | |
| SCHEMBL7915752 | 0.86 | NFE2L2 (0.79) | NFE2L2TRPA1TFEBCYP1A1CYP1A2 | |
| SCHEMBL4019329 | 0.86 | NFE2L2 (0.79) | NFE2L2TRPA1TFEBCYP1A1CYP1A2 | |
| SCHEMBL1045608 | 0.82 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL1045609 | 0.82 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1KDM4E | |
| SCHEMBL5510457 | 0.81 | NFE2L2 (0.60) | NFE2L2TRPA1TFEBCYP1A1CYP1A2 | |
| SCHEMBL5510461 | 0.81 | NFE2L2 (0.60) | NFE2L2TRPA1TFEBCYP1A1CYP1A2 | |
| SCHEMBL16933894 | 0.80 | NFE2L2 (0.64) | NFE2L2TRPA1TFEBCYP1A1CYP1A2 | |
| SCHEMBL1883472 | 0.80 | NFE2L2 (0.64) | NFE2L2TRPA1TFEBCYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | claimed |
| US-5786448-A | FOR SCREENING, SYNTHESIZING PEPTIDE DERIVATIVES | TREGA BIOSCIENCES, INC. (US) | 1998-07-28 | — | — | US | claimed |
| WO-1998019693-A1 | COMBINATORIAL LIBRARIES OF CYCLIC UREA AND CYCLIC THIOUREA DERIVATIVES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-05-14 | — | — | WO | claimed |
| CN-115141208-B | Podophyllotoxin compound containing various ester structures and preparation method and application thereof | 贵州大学 | 2024-03-08 | — | — | CN | disclosed |
| CN-115141208-A | Podophyllotoxin compound containing various ester group structures and preparation method and application thereof | 贵州大学 | 2022-10-04 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2116527-A1 | OXIME COMPOUND, PHOTOSENSITIVE COMPOSITION, COLOR FILTER, METHOD FOR PRODUCTION OF THE COLOR FILTER, AND LIQUID CRYSTAL DISPLAY ELEMENT | FUJIFILM Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-20020032325-A1 | 4-amino-3-mercapto-1,2,4-triazoles | HEINDEL NED D (US) | 2002-03-14 | — | — | US | disclosed |
| EP-1181279-A1 | DIKETODIAZACYCLIC COMPOUNDS, DIAZACYCLIC COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-1109551-A1 | 4-AMINO-3-MERCAPTO-1,2,4-TRIAZOLES | Competitive Technologies, Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000069830-A1 | DIKETODIAZACYCLIC COMPOUNDS, DIAZACYCLIC COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000010564-A1 | 4-AMINO-3-MERCAPTO-1,2,4-TRIAZOLES | COMPETITIVE TECHNOLOGIES, INC. (US) | 2000-03-02 | — | — | WO | disclosed |
| US-5786448-A | FOR SCREENING, SYNTHESIZING PEPTIDE DERIVATIVES | TREGA BIOSCIENCES, INC. (US) | 1998-07-28 | — | — | US | disclosed |
| WO-1998019693-A1 | COMBINATORIAL LIBRARIES OF CYCLIC UREA AND CYCLIC THIOUREA DERIVATIVES AND COMPOUNDS THEREIN | TREGA BIOSCIENCES, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| EP-0670831-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009159-A1 | QUINOXALINE DERIVATIVE AS ANTIDIABETIC AGENT | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1995-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | NFE2L2 418/4885TRPA1 2870/4885TFEB 3763/4885 |
| US-20020032325-A1 | 4-amino-3-mercapto-1,2,4-triazoles | TH, MAT1A, NAT1 | NFE2L2 1196/4885TRPA1 1039/4885TFEB 4602/4885 |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | NMT2, NMT1, MBOAT1 | NFE2L2 2774/4885TRPA1 4207/4885TFEB 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.